Zenas BioPharma, Inc.
ZBIO
$25.87
$1.204.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -425.15M | -377.74M | -189.90M | -177.01M | -162.76M |
| Total Depreciation and Amortization | 39.00K | 56.00K | 79.00K | 104.00K | 127.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 214.69M | 204.40M | 29.85M | 18.79M | 15.30M |
| Change in Net Operating Assets | -52.00K | 951.00K | 1.50M | 9.71M | 9.71M |
| Cash from Operations | -210.48M | -172.33M | -158.47M | -148.41M | -137.62M |
| Capital Expenditure | -2.00K | -18.00K | -92.00K | -92.00K | -127.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -134.00M | -251.87M | -162.17M | -228.97M | -116.68M |
| Cash from Investing | -134.00M | -251.89M | -162.26M | -229.06M | -116.80M |
| Total Debt Issued | 267.50M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 319.34M | 152.95M | 9.09M | 242.57M | 240.97M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 0.00 | 178.38M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 61.82M | 62.34M | 67.20M | -4.91M | -5.68M |
| Cash from Financing | 648.66M | 215.28M | 76.29M | 237.65M | 413.67M |
| Foreign Exchange rate Adjustments | -511.00K | -252.00K | -122.00K | -199.00K | 69.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 303.67M | -209.19M | -244.56M | -140.01M | 159.31M |